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but	 also	 significantly	 lowered	 their	 morbidity	 and	 mortality,	 ulti-
mately	increasing	their	quality	of	life.1	This	practice	was	soon	to	be	
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Prophylaxis	 was	 conceived	 as	 repeatedly	 dosing	 the	 patient	
so	as	to	obtain	a	measurable	factor	activity	at	all	times.	The	chal-
lenge	is	that	appropriate	dosing	regimens	vary	by	patient	and	fac-
tor	concentrate	and	should	be	 individualized	 from	a	 therapeutic	
and	economic	standpoint.6‒8	A	“trial-and-error”	approach	is	usu-
ally	 adopted,	which	 involves	 using	 a	 typical	 prophylactic	 dosing	
regimen	of	20	to	50	IU/kg,	a	dose	that	should	provide	the	average	
patient	 with	 hemophilia	 with	 enough	 clotting	 factor	 to	 achieve	
the	goal	of	a	trough	activity	≥0.01	IU/mL	at	48	hours.	However,	
this	trial-and-error	approach	fails	to	account	for	 individual	phar-
macokinetic	 (PK)	 variability	 and,	 as	 per	 Iorio	 et	 al,9 may lead to 
suboptimal	results.
The	trial-and-error	approach	is	used	again	when	switching	be-





suggest	 initiating	 extended	half-life	 (EHL)	 products	 at	 the	 same	
dose	as	standard	half-life	concentrates	but	reducing	the	infusion	
frequency	from	3	to	2	times	weekly,	and	subsequently	adjusting	
the	 dose	 based	 on	 a	 population	 pharmacokinetic	 (PopPK)	 ap-
















include	 cost	 savings,	 via	 a	 tender-based	national	 plan	 coverage	or	
otherwise,	 side	 effects,	 drug	 shortages,	 or	 hypersensitivity	 to	 the	
formulation.12
The	 optimal	 approach	 to	 dose	 selection	 when	 switching	 be-
tween	 factor	 concentrates	 remains	 unknown.	 To	 answer	 the	
question	 of	 what	 is	 known	 about	 the	 current	 use	 of	 PK	 for	 tai-
loring	 prophylaxis	 in	 people	 with	 hemophilia	 switching	 between	
factor	concentrates,	we	conducted	(1)	a	scoping	literature	review,	
searching	 for	 empirical	 evidence	 regarding	 optimal	 switching	
practice;	 and	 (2)	 a	 review	 of	 the	 Web-Accessible	 Population	
Pharmacokinetics	 Service–Hemophilia	 (WAPPS-Hemo)	 database	








network.13	 The	WAPPS-Hemo	 database	 provides	 information	 on	














strategy	 was	 developed	 using	 medical	 subject	 headings	 (MeSH).	
The	 literature	 search	 was	 independently	 performed	 in	 PUBMED	
(MEDLINE)	in	September	2018	by	both	JKY	and	ANE.	Search	terms	
included:




•	 (“Hemophilia	 A”[MeSH]	 OR	 “Hemophilia	 B”[MeSH])	 AND	
“Pharmacokinetics”







and	 other	 research	 purposes,	 as	 described	 in	 the	 WAPPS	 study	
protocols,	 approved	 by	 the	 ethics	 boards	 at	McMaster	University	
and	 the	 University	 of	 Waterloo	 and	 registered	 in	 clinicaltrial.gov	
(NCT02061072,	NCT03533504).















3.2 | Biosimilarity/bioequivalence or comparative 
PK studies
Strictly	 speaking,	 the	 term	 bioequivalence	 should	 not	 be	 used	 for	
drugs	 produced	 by	 biotechnology;	 the	 term	 biosimilarity	 is	 more	
appropriate.16	However,	bioequivalence	was	 the	 terminology	used	




standardized	dosing	protocol	 allowed	 for	 comparison	of	 individual	















Thrombosis	 and	 Haemostasis	 and	 American	 and	 European	 reg-
ulatory	 bodies.12‒14	 The	 test	 dose	 before	 and	 after	 the	 switch	
was	almost	 always	 identical,	 usually	with	a	weight-based	dosing	
of	50	IU/kg	of	the	factor	concentrates.	Using	the	same	dose	for	
different	concentrates	 is	a	 requisite	 for	biosimilarity	 studies.	All	
trials	studied	included	a	washout	period	of	between	2	and	7	days	
before	 starting	 the	 trial	 and	 between	 different	 factor	 concen-
trates	(Tables	1	and	2).
Biosimilarity/bioequivalence	 testing	 employs	 various	 types	
of	 statistics	 that	are	dependent	upon	 the	 trial	design.	Most	 trial	
designs	 for	 biosimilarity	 testing	 of	 clotting	 factors	 employed	 a	
F I G U R E  1  Study	flow	diagram	of	
WAPPS	data WAPPS Database
(n = 2785 subjects, 5152 infusions)
Subjects with >1 infusion
(n = 943 subjects, 3310 infusions)
Subjects with >1 infusion who
switched between factor concentrates
(n = 449 subjects, 1096 infusions)
1 subject associated with only 1 infusion
removed
(n = 1842 subjects, 1842 infusions)
Subjects who did not switch between factor
concentrates removed
(n = 494 subjectes, 2214 infusions)
591 switches between FVIII concentrates
(n = 394 subjectes, 985 infusions)
56 switches between FIX concentrates
(n = 55 subjectes, 111 infusions)
F I G U R E  2  Study	flow	diagram	of	
PUBMED	search
Records identified through database
searching (n = 788)
Records identified after duplicates
removed (n = 722)
Records excluded bacause of duplicates (n = 66)
Records identified after title screening
(n = 174)
Records excluded because of title screening (n = 548)
Studies excluded through abstract screening (n = 135)
Not crossover study (n = 119)
No PK evaluation (n = 6)
Not same patient on two products (n = 4)
Retrospective study (n = 4)
Not hemophilia A or B (n = 1)
Not using factor VIII or IX (n = 1)
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2	×	2	×	2	crossover	design.	All	biosimilarity	and	comparative	PK	
studies	 observed	 average	 biosimilarity	 or	 average	 mean	 PK	 pa-
rameter	 differences	 and	 did	 not	 examine	 individual	 differences.	
Average	biosimilarity	assesses	the	PK	between-subject	variability	
(BSV)	 but	 does	 not	 directly	 assess	 the	within-subject	 variability	
(WSV)	over	time.	This	may	be	reasonable	given	the	a	priori	knowl-
edge	that	clotting	factor	concentrates	demonstrate	a	high	PK	BSV	
and	 low	WSV	within	 1	 brand,6	 and	 therefore	 the	 assessment	 of	
individual	biosimilarity	may	not	be	necessary.	 Individual	biosimi-
larity	assesses	for	both	the	mean	and	variability	of	PK	metrics	and	
also	 the	 ratio	 of	 the	 2	 drug	 products	 on	 an	 individual	 basis	 and	
is	 recognized	when	both	 the	 average	biosimilarity	 is	 established	






product,	 it	 requires	 the	 same	 active	 pharmaceutical	 ingredient	













had	 very	 different	 individual	 PK	 parameters	 even	 though	 the	 av-
erage	PK	parameters	were	similar.	Similar	 findings	were	observed	






















































































TA B L E  1   (Continued)











Eighteen	 articles	were	 identified	 in	which	 their	 primary	 out-
come	 was	 focusing	 on	 inhibitor	 development	 after	 switching	
TA B L E  2  Summary	of	studies	of	hemophilia	patients	switching	between	factor	IX	concentrates
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factor	 concentrate	 products	 (Tables	 1	 and	 2).	 It	 was	 previously	
thought	 that	 switching	between	 factor	concentrates	was	associ-





































4  | PHARMACOKINETIC TARGETS 
WHEN SWITCHING
While	literature	states	the	average	of	PK	parameters	(eg,	half-life)	




in	 a	phase	3	 study	 to	determine	 the	 safety,	 efficacy,	 and	PK.	On	
average,	 the	half-life	of	Eloctate	was	1.5	 times	 that	of	Advate	at	
a	dose	of	50	 IU/kg.29,30	This	provides	valuable	 information	about	
the	population,	although	it	is	clear	from	the	breadth	of	factor	con-
centrate	 brands	 being	 switched	 to	 and	 from,	 as	 identified	 in	 the	
WAPPS-Hemo	 database,	 that	 this	 type	 of	 study	 cannot	 be	 com-
pleted	for	all	scenarios.	A	study	by	Young	et	al30	demonstrated	that	
the	individual	half-life	ratios	of	FVIII	and	Eloctate	ranged	from	0.79	





































TA B L E  3  Demographics	from	WAPPS	patients	who	have	
switched	between	factor	concentrates
Parameter Whole cohort FVIII FIX
Subjects	(n) 449 394 55
Switches	(n) 647 591 56
Age	(y) 1-78 1-78 2-68
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octocog	alfa	to	a	recombinant	FVIII	single-chain	concentrate;	how-
ever,	this	was	not	the	case	for	4	of	27	subjects.	The	potential	risk	of	
assuming	an	 increase	 in	half-life	when	switching	 from	a	standard-




It	 would	 be	 desirable	 to	 estimate	 dosing	 regimens	 across	 a	
switch	using	an	individualized	approach.	In	an	ideal	scenario,	where	
population	 PK	 tailored	 prophylaxis	was	widely	 adopted,	 patients	
planning	on	switching	to	a	different	factor	concentrate	would	have	















The	volume	of	 literature	we	expected	 to	 find	 in	 this	 specific	 field	








use.	Although	 studies	 looking	 at	 bioequivalence/biosimilarity	 or	
assessing	PK	between	2	factor	concentrates	have	led	to	PK	com-
parisons,	 these	 studies	 lack	 the	 information	 required	 to	 predict	






Given	 these	 limitations,	 further	 research	 is	 required	 to	 uti-
lize	PK	parameters	 from	 the	origin	product	 to	predict	 the	PK	of	
the	destination	product	 in	patients	with	hemophilia.	Due	to	sim-


























Switch	from Plasma-derived 4 1 0 11 1 17
Recombinant 0 1 1 22 7 31
Recombinant 
glycoPEGylated
0 0 0 0 0 0
Recombinant	Fc-
fusion	protein
1 0 1 0 5 7
Recombinant albu-
min	fusion	protein
0 0 0 1 0 1
Total 5 2 2 34 13 56
FIX,	factor	IX;	WAPPS,	Web-Accessible	Population	Pharmacokinetics	Service.
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